Funds to the Tune of $18 Million Secured for Ready-to-Use Stem Cell Treatments for Pets' Medical Needs, as per Gallant's Announcement
**Gallant Secures $18 Million in Series B Funding for Pet Stem Cell Therapies**
Gallant, an innovative animal health biotechnology company, has secured $18 million in Series B funding to accelerate the development and initial commercial rollout of off-the-shelf stem cell therapies for pets. This funding round, led by Digitalis Ventures, will primarily focus on addressing challenging conditions such as Feline Chronic Gingivostomatitis (FCGS), Canine Osteoarthritis (COA), Feline Chronic Kidney Disease (CKD), and more.
The funding will be utilized to advance the first ready-to-use stem cell therapy for refractory FCGS towards anticipated conditional FDA approval in early 2026. This could mark a significant milestone as the first FDA-labeled, allogeneic stem cell therapy in veterinary medicine. The lead product for FCGS is expected to bring regenerative medicine solutions to pets sooner, providing a much-needed alternative to current treatments that only manage symptoms rather than the root cause.
In addition to the FCGS therapy, the funding will support the development of a pipeline of stem cell therapies aimed at other common and underserved diseases in pets. These include COA, Canine Atopic Dermatitis (CAD), and Feline CKD, where current treatments often fall short.
Digitalis Ventures, along with new participants NovaQuest Capital Management, BOLD Capital, and Hill Creek Partners, will support rigorous, FDA-aligned studies and regulatory processes to ensure the quality, consistency, and safety of these therapies. The funding will also enhance Gallant’s proprietary platform based on uterine-derived mesenchymal stem cells, designed to reduce inflammation, restore tissue function, and support long-term recovery in pets.
Teymour Boutros-Ghali, Managing Partner at BOLD Capital, commends Gallant for bringing the same caliber of science to animal health with off-the-shelf therapies for pets. He believes that regenerative medicine is entering its prime and that Gallant's advancements in a new class of therapies and movement towards commercialization are exciting.
NovaQuest Capital Management's participation is notable due to its experience with Mesoblast, whose product RYONCIL became the first FDA-approved human allogeneic mesenchymal stromal cell (MSC) therapy in the U.S. in December 2024. Brian Axe, Partner at NovaQuest, expresses optimism about delivering a breakthrough therapy for animal health, referencing the FDA approval of the first human allogeneic stem cell therapy as a historic milestone.
By focusing on these strategic areas, Gallant aims to bring transformative veterinary regenerative medicine into everyday clinical practice, helping pets heal at the source rather than just managing symptoms. The anticipated conditional approval of the FCGS therapy may offer new treatment options for cats with this condition and help establish regulatory pathways for future stem cell therapies.
With this funding, Gallant aims to create a new category in veterinary care with ready-to-use stem cell therapies for common diseases in dogs and cats. The company's mission remains steadfast: to make stem cell therapy accessible to pets in need.
[1] Gallant's $18 million Series B funding will be primarily utilized to accelerate the development and initial commercial rollout of its off-the-shelf stem cell therapies for pets, with a focus on challenging conditions such as Feline Chronic Gingivostomatitis (FCGS), Canine Osteoarthritis (COA), Feline Chronic Kidney Disease (CKD), among others. [2] This funding round, led by Digitalis Ventures and supported by investors like NovaQuest Capital Management, BOLD Capital, and Hill Creek Partners, will specifically enable the advancement of the first ready-to-use stem cell therapy for refractory FCGS toward anticipated conditional FDA approval expected in early 2026, which could be the first FDA-labeled, allogeneic stem cell therapy in veterinary medicine. [5] By focusing on these strategic areas, Gallant aims to bring transformative veterinary regenerative medicine into everyday clinical practice, helping pets heal at the source rather than just managing symptoms.
- The funding for Gallant's pet stem cell therapies, primarily intended for addressing medical-conditions like Feline Chronic Gingivostomatitis (FCGS), Canine Osteoarthritis (COA), and Feline Chronic Kidney Disease (CKD), will be used to advance science and technology in health-and-wellness for animals.
- With the support of Digitalis Ventures, NovaQuest Capital Management, BOLD Capital, and Hill Creek Partners, Gallant's target is to bring transformative technologies in regenerative medicine to pets, promising a shift from managing symptoms to healing at the source, akin to advancements in human medical-conditions.
